As the patients enrolled were chemotherapy-nave for metastatic disease, 97

As the patients enrolled were chemotherapy-nave for metastatic disease, 97.5% had received prior adjuvant therapy. other antiangiogenic agents, such as bevacizumab and regorafenib. Keywords:aflibercept, angiogenesis, colorectal malignancy == Introduction == Colorectal malignancy (CRC) is the fourth most common cause of death from malignancy worldwide, accounting for approximately 8% of all cancer deaths.1Nearly 25% of patients will present with distant metastases; up to half of those with earlier-stage presentations will eventually progress to metastatic disease. 2These patients currently carry a poor prognosis, with a 5-12 months survival rate of approximately 10%.3Recent research in metastatic CRC (mCRC) has focused primarily around the addition of biological target-oriented therapies to combination cytotoxic chemotherapy regimens. The monoclonal antibody bevacizumab, which binds and blocks the proangiogenic factor vascular endothelial growth factor (VEGF)-A, was the first successful targeted therapy in mCRC and the first antiangiogenic agent approved for use in malignancy. The incorporation of antiangiogenic brokers into the treatment of mCRC has led to improved antitumor responses and increased survival. Ziv-aflibercept is usually a recombinant inhibitor of the VEGF pathway. This short article aims to review the data supporting its use in mCRC and its role in current practice. It will also provide an overview of tumor angiogenesis, with a focus on the VEGF signaling pathway. == Tumor angiogenesis == Angiogenesis, the formation of new blood vessels from existing vessels, is an essential process in tissue development and growth. These blood vessels facilitate the delivery of necessary oxygen and nutrients, as well as the removal of waste products. Angiogenesis is normally finely coordinated Cd200 through the balance and conversation of proangiogenic and antiangiogenic signaling pathways. 4Proangiogenic factors such as VEGF are appropriately upregulated in a number of physiologic Mavoglurant settings, including embryogenesis, bone formation, wound healing, and ovarian follicle growth. Dysregulation of angiogenesis plays a key role in certain diseases, such as arthritis, psoriasis, macular degeneration, diabetic retinopathy, and malignancy.5 Pathologic angiogenesis is a key component of cancer growth6and a necessary course of action for tumor metastasis.7Tumor growth beyond 23 mm has been shown to be dependent on angiogenesis.8An angiogenic switch has been described as a discrete step in the progression Mavoglurant of tumors, required before they develop the potential for increased size, invasion, and metastasis. This switch can involve the overexpression of proangiogenic factors and increased sensitivity to these factors.9 In the majority of cancers, tumor angiogenesis proceeds by promoting vessel dilation and perivascular detachment in normal vessels in the vicinity of the tumor. This leaves them susceptible to the migration of rapidly recruited endothelial cells necessary for sprouting angiogenesis and the formation of new blood vessels branching off from existing vessels.9,10Some tumors, such as astrocytomas, instead progress initially by growing along and co-opting normal blood vessels. As these tumors enlarge beyond the protection of these co-opted vessels, they develop regions of hypoxia and necrosis. Factors brought on by these conditions, in turn, promote sprouting angiogenesis to support continued tumor growth.9,11The blood vessels formed in tumors are irregular and tortuous. They form chaotically, without the hierarchy seen in normal vessels. This network is usually often leaky and predisposed to hemorrhage. 9Dysfunctional blood flow in these vessels may result in further ischemia, driving additional angiogenesis and leading to increased microvessel density. Intratumor microvessel density has been proposed as a prognostic factor Mavoglurant in a number of cancers. 12The permeable vasculature may also provide convenience for tumor cell invasion as a step in metastasis.13 == The VEGF pathway == The VEGF signaling pathway is the best understood angiogenic pathway. The VEGF ligand family in humans consists of 5 glycoproteins, VEGF-A, VEGF-B, VEGF-C, VEGF-D, and placental growth factor (PlGF). These Mavoglurant bind to three individual receptor tyrosine kinases (RTKs), VEGF receptor (VEGFR)-1 (FLT-1), VEGFR-2 (KDR/FLK-1), and VEGFR-3 (FLT-4), which are found primarily on the surface of vascular and lymphatic endothelial cells. Two neuropilins, NRP-1 and NRP-2, act as coreceptors for VEGFRs, increasing the binding affinity of.